Articles

  • Aug 31, 2023 | bioworld.com | Meg Bryant

    Regeneron’s ultra-rare disease drug for Chaple disease is approved by the FDAThe U.S. FDA has approved its second treatment for an ultra-rare disease in the past three days by greenlighting Veopoz (pozelimab-bbfg) from Regeneron...

  • Aug 28, 2023 | bioworld.com | Meg Bryant

    Viz.ai poised to take a bite out of hypertrophic cardiomyopathy with FDA de novoHypertrophic cardiomyopathy (HCM) might not be the talk of the town in the world of cardiology medical devices, but the condition has a devastating effect on a...

  • Aug 25, 2023 | bioworld.com | Meg Bryant

    Viz.ai poised to take a bite out of hypertrophic cardiomyopathy with FDA de novoHypertrophic cardiomyopathy (HCM) might not be the talk of the town in the world of cardiology medical devices, but the condition has a devastating effect on a...

  • Aug 23, 2023 | bioworld.com | Meg Bryant

    Headset could improve safety of return-to-play decisions after concussionFor many sports injuries, return-to-play decisions are pretty straightforward: pain and swelling have dissipated, or an X-ray confirms that a bone has healed. For concussion, it’s not so clear. Though symptoms may resolve after a few days, the brain could still be vulnerable. Now, Cupertino, Calif.-based based startup Mindrhythm Inc.

  • Aug 15, 2023 | bioworld.com | Meg Bryant

    At first ASGCT Immuno-oncology meeting, ways to build better T cells“From such a stick, such a splinter,” is a popular Spanish saying to explain how a son resembles his father. Like father, like son. The first Spotlight on...

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →